A study of hydroxychloroquine as post exposure prophylaxis for SARS-CoV-2 (HOPE trial)
- Conditions
- Certain infectious and parasitic diseases
- Registration Number
- KCT0004907
- Lead Sponsor
- Yonsei University Health System, Gangnam Severance Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 2486
? A person who is classified as a contact person from a confirmed patient who has confirmed SARS-CoV-2
? Medical staff exposed from confirmed persons in hospitals where SARS-CoV-2 infection has occurred
? Persons exposed to COVID-19 in certain workplaces, religious groups, military outbreak
* Subjects of study include both asymptomatic and bequest boxes as contacts of confirmed patients.
Hypersensitivity to Chloroquine or HCQ
Those who are contraindicated in HCQ administration according to the permission requirements, such as pregnant women, lactating women, women who may be pregnant, women with visual impairments, eye diseases such as macular disease, and patients with porphyria
Human immunodeficiency virus (HIV) infection
Patients with autoimmune disease (Systemic lupus erythematosus, Mixed connective tissue disease)
Autoimmune inflammatory rheumatic diseases (AIIRD)-Ankylosing spondylitis
Arrhythmia, cirrhosis of Child Pugh C, chronic kidney failure with eGFR <30mL / min / 1.73m2 (non-dialysis patients)
A person who is positive in the COVID-19 screening test before taking preventive medication
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method rate of COVID-19 conversion
- Secondary Outcome Measures
Name Time Method serology test